PMID- 21060749
OWN - NLM
STAT- MEDLINE
DCOM- 20110407
LR  - 20211020
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Print)
IS  - 1011-8934 (Linking)
VI  - 25
IP  - 11
DP  - 2010 Nov
TI  - Clinical benefit of low molecular weight heparin for ST-segment elevation 
      myocardial infarction patients undergoing primary percutaneous coronary 
      intervention with glycoprotein IIb/IIIa inhibitor.
PG  - 1601-8
LID - 10.3346/jkms.2010.25.11.1601 [doi]
AB  - The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated 
      heparin (UFH) during percutaneous coronary intervention (PCI) with or without 
      glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa 
      inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 
      patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in 
      the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either 
      of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp 
      IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to 
      the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end 
      points were cardiac death or myocardial infarction during the 30 days after the 
      registration. The primary end point occurred in 4.1% (9/219) of patients managed 
      with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8% (28/257) of patients 
      managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95% 
      confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial 
      Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp 
      IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For patients with 
      STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more 
      beneficial than UFH.
FAU - Cho, Jung Sun
AU  - Cho JS
AD  - Cardiovascular Center, Seoul St. Mary's Hospital, Seoul, Korea.
FAU - Her, Sung-Ho
AU  - Her SH
FAU - Baek, Ju Yeal
AU  - Baek JY
FAU - Park, Mahn-Won
AU  - Park MW
FAU - Kim, Hyoung Doo
AU  - Kim HD
FAU - Jeong, Myung Ho
AU  - Jeong MH
FAU - Ahn, Young keun
AU  - Ahn Yk
FAU - Chae, Shung Chull
AU  - Chae SC
FAU - Hur, Seung Ho
AU  - Hur SH
FAU - Hong, Taek Jong
AU  - Hong TJ
FAU - Kim, Young Jo
AU  - Kim YJ
FAU - Seong, In Whan
AU  - Seong IW
FAU - Chae, Jei Keon
AU  - Chae JK
FAU - Rhew, Jay Young
AU  - Rhew JY
FAU - Chae, In Ho
AU  - Chae IH
FAU - Cho, Myeong Chan
AU  - Cho MC
FAU - Bae, Jang Ho
AU  - Bae JH
FAU - Rha, Seung Woon
AU  - Rha SW
FAU - Kim, Chong Jim
AU  - Kim CJ
FAU - Choi, Donghoon
AU  - Choi D
FAU - Jang, Yang Soo
AU  - Jang YS
FAU - Yoon, Junghan
AU  - Yoon J
FAU - Chung, Wook Sung
AU  - Chung WS
FAU - Cho, Jeong Gwan
AU  - Cho JG
FAU - Seung, Ki Bae
AU  - Seung KB
FAU - Park, Seung Jung
AU  - Park SJ
CN  - Korea Acute Myocardial Infarction Registry Investigators
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101026
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage
MH  - Heparin/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Myocardial Infarction/epidemiology/mortality/*therapy
MH  - Myocardial Revascularization
MH  - Odds Ratio
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors/metabolism
MH  - Prognosis
MH  - Registries
PMC - PMC2966997
OTO - NOTNLM
OT  - Blood Platelets
OT  - Heparin
OT  - Myocardial Infarction
OT  - Prognosis
FIR - Jeong, Myung Ho
IR  - Jeong MH
FIR - Kim, Young Jo
IR  - Kim YJ
FIR - Kim, Chong Jin
IR  - Kim CJ
FIR - Cho, Myeong Chan
IR  - Cho MC
FIR - Ahn, Young Keun
IR  - Ahn YK
FIR - Kim, Jong Hyun
IR  - Kim JH
FIR - Chae, Shung Chull
IR  - Chae SC
FIR - Hur, Seung Ho
IR  - Hur SH
FIR - Seong, In Whan
IR  - Seong IW
FIR - Hong, Taek Jong
IR  - Hong TJ
FIR - Choi, Dong Hoon
IR  - Choi DH
FIR - Chae, Jei Keon
IR  - Chae JK
FIR - Rhew, Jae Young
IR  - Rhew JY
FIR - Kim, Doo Il
IR  - Kim DI
FIR - Chae, In Ho
IR  - Chae IH
FIR - Yoon, Junghan
IR  - Yoon J
FIR - Koo, Bon Kwon
IR  - Koo BK
FIR - Kim, Byung Ok
IR  - Kim BO
FIR - Lee, Myoung Yong
IR  - Lee MY
FIR - Kim, Kee Sik
IR  - Kim KS
FIR - Hwang, Jin Yong
IR  - Hwang JY
FIR - Oh, Seok Kyu
IR  - Oh SK
FIR - Lee, Nae Hee
IR  - Lee NH
FIR - Jeong, Kyoung Tae
IR  - Jeong KT
FIR - Tahk, Seung Jea
IR  - Tahk SJ
FIR - Bae, Jang Ho
IR  - Bae JH
FIR - Rha, Seung Woon
IR  - Rha SW
FIR - Park, Keum Soo
IR  - Park KS
FIR - Han, Kyoo Rok
IR  - Han KR
FIR - Ahn, Tae Hoon
IR  - Ahn TH
FIR - Kim, Moo Hyun
IR  - Kim MH
FIR - Yang, Joo Young
IR  - Yang JY
FIR - Rhim, Chong Yun
IR  - Rhim CY
FIR - Gwon, Hyeon Cheol
IR  - Gwon HC
FIR - Park, Seong Wook
IR  - Park SW
FIR - Koh, YoungYoup
IR  - Koh Y
FIR - Joo, Seung Jae
IR  - Joo SJ
FIR - Kim, Soo Joong
IR  - Kim SJ
FIR - Jin, Dong Kyu
IR  - Jin DK
FIR - Cho, Jin Man
IR  - Cho JM
FIR - Chung, Wook Sung
IR  - Chung WS
FIR - Jang, Yang Soo
IR  - Jang YS
FIR - Cho, Jeong Gwan
IR  - Cho JG
FIR - Seung, Ki Bae
IR  - Seung KB
FIR - Park, Seung Jung
IR  - Park SJ
EDAT- 2010/11/10 06:00
MHDA- 2011/04/08 06:00
PMCR- 2010/11/01
CRDT- 2010/11/10 06:00
PHST- 2010/05/04 00:00 [received]
PHST- 2010/06/16 00:00 [accepted]
PHST- 2010/11/10 06:00 [entrez]
PHST- 2010/11/10 06:00 [pubmed]
PHST- 2011/04/08 06:00 [medline]
PHST- 2010/11/01 00:00 [pmc-release]
AID - 10.3346/jkms.2010.25.11.1601 [doi]
PST - ppublish
SO  - J Korean Med Sci. 2010 Nov;25(11):1601-8. doi: 10.3346/jkms.2010.25.11.1601. Epub 
      2010 Oct 26.